Sanofi (SNY)

44.17
0.69 1.59
NYSE : Health Technology
Prev Close 43.48
Open 44.18
Day Low/High 43.51 / 44.38
52 Wk Low/High 37.43 / 45.86
Volume 1.20M
Avg Volume 1.24M
Exchange NYSE
Shares Outstanding 2.58B
Market Cap 107.76B
EPS 1.70
P/E Ratio 23.50
Div & Yield 1.20 (2.84%)
Sanofi Said to Be Near $1 Billion Deal for Flexion

Sanofi Said to Be Near $1 Billion Deal for Flexion

Flexion is an arthritis-focused biotech company.

Egalet Makes Friday's Biotech Mailbag

Egalet Makes Friday's Biotech Mailbag

Why the name is sagging, and what it will take to spur the sector higher.

Amgen: Clinical Trials Set Stage for Further Upside

Amgen: Clinical Trials Set Stage for Further Upside

This biotech name shows no sign of slowing down.

4 Smaller Biotech Names Worth Researching

4 Smaller Biotech Names Worth Researching

Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.

Amicus CEO John Crowley, Not His Daughter Megan, Might Compel Trump to Make Big Changes at FDA

Amicus CEO John Crowley, Not His Daughter Megan, Might Compel Trump to Make Big Changes at FDA

Absent specific policy details, Trump's speech leaves investors guessing about his real plans for the FDA and the drug approval process. He has not yet named an FDA commissioner.

15 Remakes and Sequels Coming to the Silver Screen in 2017

15 Remakes and Sequels Coming to the Silver Screen in 2017

Hollywood's lack of originality shines through with 15 remakes and sequels this year.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Sanofi's Base Pattern Should Make Investors Happy

Sanofi's Base Pattern Should Make Investors Happy

SNY has become much stronger since late October; buy here and above $44.

Clovis, Tesaro Soar on Astrazeneca Phase Three News

Clovis, Tesaro Soar on Astrazeneca Phase Three News

AstraZeneca shares, meanwhile, were less-than-moved by the news.

Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta

Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

DexCom Is a Great Healthcare Stock to Buy Now

DexCom Is a Great Healthcare Stock to Buy Now

The continuous glucose monitor maker is an excellent growth opportunity.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Mylan Shares Unchanged as Kaleo Releases EpiPen Competitor

Mylan Shares Unchanged as Kaleo Releases EpiPen Competitor

The Auvi-Q was released Feb. 14, but it's unclear whether patients will break up with their current option, EpiPen, for something new.

Biotech Tesaro Climbs on Takeout Reports

Biotech Tesaro Climbs on Takeout Reports

The company's shares were up 14% on rumors that it is working with investment banks to consider a sale.

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Biopharma's reticence suggests that fear of Trump's tweets and threats to limit drug pricing (and cut into profits) has stopped biotech companies from standing up for what's right.

Hagens Berman: Insulin Manufacturers Hit With Class-Action Lawsuit Over Drug Price Inflation Scheme And RICO Violations - Time To Break Up The Insulin Racket

People living with diabetes have filed a groundbreaking class-action lawsuit against the three makers of analog insulin drug products - Sanofi, Novo Nordisk and Eli Lilly - for exponentially raising consumer insulin prices...

7 Things to Watch in Biotech Now

7 Things to Watch in Biotech Now

M&A, drug approvals and Trump are all on my watch list.

Express Scripts, Cigna Opt Out of Paying for EpiPen Competitor Auvi-Q

Express Scripts, Cigna Opt Out of Paying for EpiPen Competitor Auvi-Q

It's unclear how much of the hefty $4,500 price pharmacy benefit managers or insurers will agree to pay to keep Auvi-Q free for most patients.

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Other movers included Mannkind, Perrigo and Bristol-Myers Squibb.

Regeneron Pharmaceuticals Could Be Ready to Rebound

Regeneron Pharmaceuticals Could Be Ready to Rebound

Regeneron has faced a lower stock price and patent wrangling. But the stock could be ready to rise again.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

5 Rocket Stocks for 2017 -- Amgen, eBay, More

5 Rocket Stocks for 2017 -- Amgen, eBay, More

These stocks are showing short-term gain catalysts and longer-term growth potential. Here's how to trade them.

Here's Why Teva Shares Are Plummeting

Here's Why Teva Shares Are Plummeting

Shares fall on worse-than-expected guidance. It was not a good day for Teva Pharmaceuticals.

Jim Cramer Sees Buying Opportunities in Praluent Patent Suit

Jim Cramer Sees Buying Opportunities in Praluent Patent Suit

After a court halts Regeneron's sales of Praluent, Jim Cramer sees opportunity in Amgen.

Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View

Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View

The Medicines Company, Alder also see share boosts on favorable implications. Jim Cramer weighs in on the implications for Amgen investors.

Regeneron Cholesterol-Lowering Drug Banned From U.S. Market

Regeneron Cholesterol-Lowering Drug Banned From U.S. Market

A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.

5 Things You Must Know Before the Market Opens Friday

5 Things You Must Know Before the Market Opens Friday

U.S. stock futures trade slightly lower Friday ahead of the U.S. jobs report for December, the last under the Obama presidency.

Sanofi Investors Have Worst Day in Six Months

Sanofi Investors Have Worst Day in Six Months

Praluent Infringes on Amgen's patents for rival drug, Repatha, a ruling says.

After Stunning Loss to Amgen in Patent Case, Regeneron Plans to Join Sanofi in Appeal

After Stunning Loss to Amgen in Patent Case, Regeneron Plans to Join Sanofi in Appeal

A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.

TheStreet Quant Rating: B (Buy)